15.59
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment - MSN
Why pension funds invest in KalVista Pharmaceuticals Inc. (4XC1) stockWeekly Profit Analysis & High Conviction Buy Zone Alerts - Newser
Will KalVista Pharmaceuticals Inc. (4XC1) stock profit from automation waveJuly 2025 Review & Safe Capital Investment Plans - Newser
How KalVista Pharmaceuticals Inc. stock reacts to inflationary pressures2025 EndofYear Setup & Free High Return Stock Watch Alerts - Newser
Is KalVista Pharmaceuticals Inc. stock a contrarian buyJuly 2025 Price Swings & Verified Momentum Stock Alerts - Newser
Behavioral Patterns of KALV and Institutional Flows - news.stocktradersdaily.com
KalVista Pharma CMO Audhya sells $71k in stock By Investing.com - Investing.com South Africa
KalVista Pharmaceuticals Stock (KALV) Opinions on Q3 Revenue Success - Quiver Quantitative
KALV SEC FilingsKalvista Pharm 10-K, 10-Q, 8-K Forms - Stock Titan
KalVista Pharma CFO Piekos sells $60k in shares By Investing.com - Investing.com Canada
KalVista Pharma exec Yea sells $58k in shares By Investing.com - Investing.com Nigeria
KalVista Pharma CMO Audhya sells $71k in stock - Investing.com
KalVista Pharma exec Yea sells $58k in shares - Investing.com
KalVista Pharmaceuticals Executives Sell Shares for Tax Obligations - TradingView
Officer Audhya Acquires 5,954 Of KalVista Pharmaceuticals Inc [KALV] - TradingView
KalVista Pharmaceuticals, Inc. (KALV) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Is KalVista Pharmaceuticals Inc. stock positioned well for digital economyGap Down & High Conviction Buy Zone Picks - newser.com
Real time scanner hits for KalVista Pharmaceuticals Inc. explainedQuarterly Earnings Summary & AI Powered Buy and Sell Recommendations - newser.com
Multi asset correlation models including KalVista Pharmaceuticals Inc.July 2025 Trends & Consistent Profit Trade Alerts - newser.com
What makes KalVista Pharmaceuticals Inc. stock attractive to growth funds2025 Earnings Surprises & Stock Portfolio Risk Control - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock keep high P E multiplesQuarterly Portfolio Review & Consistent Growth Equity Picks - newser.com
Citizens reiterates Market Outperform rating on Kalvista stock at $28 target - Investing.com Canada
How to manage a losing position in KalVista Pharmaceuticals Inc.Watch List & Fast Gaining Stock Strategy Reports - newser.com
What market sentiment indicators show for KalVista Pharmaceuticals Inc. (4XC1) stockQuarterly Investment Review & Low Drawdown Momentum Ideas - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock benefit from commodity supercycle2025 Institutional Moves & Real-Time Volume Analysis - newser.com
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects - Insider Monkey
10 Best Breakout Stocks to Invest In - Insider Monkey
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates - MSN
How KalVista Pharmaceuticals Inc. stock performs in high volatility marketsEarnings Recap Report & AI Based Buy and Sell Signals - newser.com
How hedge fund analytics apply to KalVista Pharmaceuticals Inc. stockJuly 2025 Review & Reliable Momentum Entry Alerts - newser.com
How strong is KalVista Pharmaceuticals Inc. (4XC1) stock earnings growthAnalyst Upgrade & Safe Entry Zone Tips - newser.com
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):